11/7
11:30 pm
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
High
Report
CytomX Therapeutics (NASDAQ:CTMX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
11/7
11:30 pm
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
High
Report
CytomX Therapeutics (NASDAQ:CTMX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
10/21
07:48 am
ctmx
Rating for CTMX
Medium
Report
Rating for CTMX
10/21
07:48 am
ctmx
Rating for CTMX
Medium
Report
Rating for CTMX
10/21
06:02 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
9/23
06:11 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
9/22
08:24 am
ctmx
Rating for CTMX
Low
Report
Rating for CTMX
9/22
07:49 am
ctmx
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
Low
Report
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
9/22
06:34 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
CytomX Therapeutics (NASDAQ:CTMX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
9/22
06:06 am
ctmx
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
Medium
Report
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
9/18
06:44 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
9/17
08:05 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC. They now have a $3.50 price target on the stock.
Low
Report
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC. They now have a $3.50 price target on the stock.
9/17
07:10 am
ctmx
Rating for CTMX
Medium
Report
Rating for CTMX
9/17
07:10 am
ctmx
Rating for CTMX
Medium
Report
Rating for CTMX
9/16
04:19 pm
ctmx
CytomX Therapeutics initiated with an Overweight at Barclays
Medium
Report
CytomX Therapeutics initiated with an Overweight at Barclays
9/16
04:19 pm
ctmx
CytomX Therapeutics initiated with an Overweight at Barclays
Medium
Report
CytomX Therapeutics initiated with an Overweight at Barclays